JNJ - Johnson & Johnson

NYSE - NYSE Delayed Price. Currency in USD
138.10
+0.81 (+0.59%)
At close: 4:00PM EDT

137.60 -0.50 (-0.36%)
After hours: 5:53PM EDT

Stock chart is not supported by your current browser
Previous Close137.29
Open137.00
Bid137.61 x 2200
Ask138.08 x 1100
Day's Range136.95 - 138.78
52 Week Range118.62 - 148.99
Volume5,765,119
Avg. Volume7,524,941
Market Cap367.729B
Beta (3Y Monthly)0.66
PE Ratio (TTM)24.63
EPS (TTM)5.61
Earnings DateApr 16, 2019
Forward Dividend & Yield3.60 (2.60%)
Ex-Dividend Date2019-02-25
1y Target Est144.71
Trade prices are not sourced from all markets
  • Reuters4 hours ago

    J&J to record $700 million charge related to abandoned drug program

    (Reuters) - Johnson & Johnson on Thursday said https://www.sec.gov/Archives/edgar/data/200406/000020040619000016/a20190321alios8-k.htm it will record a nearly $700 million (£536.4 million) impairment charge ...

  • Reuters4 hours ago

    J&J to record $700 mln charge related to abandoned drug program

    Johnson & Johnson on Thursday said https://www.sec.gov/Archives/edgar/data/200406/000020040619000016/a20190321alios8-k.htm it will record a nearly $700 million impairment charge in the first quarter of ...

  • CNBC4 hours ago

    Cramer: Investors need a new playbook now that the Fed ended rate hikes this year

    "We don't need to worry about more rate hikes—and that's why it's causing a sea change in the stock market right now because we're in a low growth environment again," CNBC's Jim Cramer says. Cramer explains what stocks are good to buy in a low-growth environment and which stocks to stay away from. Investors need not worry that the Federal Reserve induced a market "sea change" by calling off interest rate increases this year and adjust their game plan to make money, CNBC's Jim Cramer said Thursday.

  • Here’s What the Apple Watch Means for AAPL Stock
    InvestorPlace6 hours ago

    Here’s What the Apple Watch Means for AAPL Stock

    It's become increasingly clear over the past few months that Apple (NASDAQ:AAPL) can no longer rely on the iPhone alone. That realization initially tanked Apple stock, which dropped nearly 40% between early October and late December. Of late, however, investors have become more comfortable with that pivot: AAPL stock already has gained nearly 20% so far in 2019.Source: Shutterstock The bull case for Apple stock, as Luke Lango argued this month, is that services revenue can offset hardware pressure. With Apple stock still cheap (it trades at less than 15x forward earnings), even modest growth is enough.Add in the fact that Apple still has more cash on its balance sheet than any company in history, and it doesn't take smashing success for AAPL to move higher.InvestorPlace - Stock Market News, Stock Advice & Trading TipsThe bear case, which I laid out in detail last year, is that the iPhone simply is too important. The product still drives 60% of revenue. And with Apple's market capitalization nearly $900 billion, what would be a hit for another company barely moves the needle for Apple. * 7 Beaten-Up Stocks to Buy as They Reverse Course The Apple Watch is an interesting microcosm of that bull/bear debate. And news this week of a landmark study involving the product adds an intriguing layer to the argument.From one standpoint, the Apple Watch could be a key part of the transformation of Apple and AAPL stock. From another, it hardly matters at all. The Apple Watch StudyOn Monday, researchers from Apple and Stanford Medicine released the results of a massive study involving the Apple Watch. Some 419,000 subjects participated over eight months. Those individuals wore the target smartwatches with the capability to detect abnormal heartbeats.The results aren't conclusive. Roughly 0.5% of the participants received notice of an irregular pattern. Unsurprisingly, the rate was higher in older patients.Of those who received a notice, only about 20% followed up by wearing a patch to confirm the diagnosis. Of that group, 34% received a confirmed diagnosis. But in a smaller group of subjects who wore both a patch and the Apple Watch, 84% of atrial fibrillation cases detected by the path were also picked up by the Watch.On the whole, the study does seem like good news for Apple (and for patients). There are concerns about false positives from the technology. However, the innovation is constantly improving and will benefit from further tweaking. As one cardiologist told CNBC, the results were "moderately good for a screening tool, but not amazing." That description could change over time, and more studies should give a better understanding of just how effective the Apple Watch is.The study doesn't prove that the Apple Watch can be a successful cardiac screening tool, at least not yet. A two-in-three false positive rate might be too problematic for some (or most) doctors. But at the least, the study does show that Apple might be on the right path in terms of developing life-saving -- and profitable -- technology. Does It Matter for AAPL Stock?From an investment standpoint, the question is whether even success here is enough. Again, this is a nearly $900 billion company. Fitbit (NYSE:FIT), whose smartwatch category the Apple Watch has taken over, has an enterprise value well under $1 billion.Apple hasn't broken out its smartwatch revenue. But sales of "other products" -- including Apple Watch, AirPods, Apple TV, Beats and other smaller lines -- in fiscal year 2018 were $17.4 billion, according to the 10-K. CFO Luca Maestri last year said AirPods and Apple Watch combined were driving over $10 billion annually in revenue.That's a big number. But the revenue from other products (now called "Wearables, Home and Accessories") still is about 7% of trailing-twelve-month revenue after driving 8.7% of first-quarter sales. Assuming its smartwatch revenue is $7-8 billion (roughly half of that category), it still drives maybe 3% of total corporate revenue. Even modest declines in iPhone revenue will more than offset growth in the Apple Watch. The Services Case for Apple StockSo it's easy perhaps to argue that the smartwatch division simply isn't enough. But where the story gets interesting is not just in hardware sales, but how the company can monetize the services side of the product. Healthcare giant Johnson & Johnson (NYSE:JNJ) is joining in the next controlled study of the Apple Watch. And the product itself could be the tip of the spear in the company's healthcare strategy.Back in January, Dana Blankenhorn detailed that strategy and the ways in which AAPL stock could profit from healthcare services. Monitoring revenues could be large. DexCom (NASDAQ:DXCM) is a $13 billion company built off the back of a continuous glucose monitoring system for diabetes. Other tech giants, including Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL), are looking to profit from the intersection of medicine and technology. However, the Apple Watch puts the company into millions of homes, a huge head start.I still question whether it's enough. Even the development of a DexCom-sized business adds less than 2% to Apple's market capitalization. But combined with efforts elsewhere in services, in content, and through share buybacks, there's an argument that Apple can keep profits intact in the near-term before eventually driving growth again.That's the strategy needed to keep AAPL stock moving higher, particularly with the year-to-date rally. How investors view the potential of the Apple Watch given recent developments might show how they will view the possibilities of Apple's larger pivot away from its reliance on hardware … and just how successful that strategy is going to be.As of this writing, Vince Martin has no positions in any securities mentioned. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Specialty Retail ETFs to Buy the Industry's Disruption * 5 Stocks To Buy for the Happiest Employees * 3 Out-of-Favor Consumer Stocks to Buy Compare Brokers The post Here's What the Apple Watch Means for AAPL Stock appeared first on InvestorPlace.

  • 11 Dividend Stocks With 55 or More Years of Payout Growth
    Kiplinger7 hours ago

    11 Dividend Stocks With 55 or More Years of Payout Growth

    Long-term income investors know that finding dividend stocks with decades of interrupted payments is only part of the winning formula for income investing. Dividend growth matters, too - which is exactly why investors cherish the Dividend Aristocrats.Dividend Aristocrats are companies in the Standard & Poor's 500-stock index that have hiked their dividends every year for at least 25 consecutive years. Rising dividends naturally make these stocks more attractive to new income investors, and steady payout hikes reward existing investors with increasingly higher yields on their shares' original buy-in cost.Most importantly, regular dividend hikes fuel the magic of compounding. Indeed, many of the best stocks of all time have long histories of dividend growth.Since reliable dividend stocks with growing payouts can provide some comfort amid market uncertainty, we took a look at the 11 Dividend Aristocrats with the longest histories of annual dividend increases. After all, when a dividend stock manages to raise its payout through good times and bad, decade after decade, you know management is making its income-reliant shareholders a top priority. SEE ALSO: The Kiplinger Dividend 15: Our Favorite Dividend-Paying Stocks

  • Cooper Companies' (COO) CooperVision Gains Momentum Globally
    Zacks12 hours ago

    Cooper Companies' (COO) CooperVision Gains Momentum Globally

    Cooper Companies (COO) maintains its leading position in the markets of specialty lenses, supported by highly exclusive products like Biofinity and Clariti.

  • Alkermes Focuses on Pipeline, Depends on Partners for Funds
    Zacks12 hours ago

    Alkermes Focuses on Pipeline, Depends on Partners for Funds

    Alkermes (ALKS) has an impressive pipeline and is focused on the development of its candidates.

  • Dear Apple, Is My Heart OK?
    Motley Fool14 hours ago

    Dear Apple, Is My Heart OK?

    Results from the Apple Heart Study suggest wearables like watches could someday reshape healthcare.

  • Microsoft Stock Is Just Too Good to Buy Right Now
    InvestorPlace14 hours ago

    Microsoft Stock Is Just Too Good to Buy Right Now

    Microsoft (NASDAQ:MSFT) continues zooming to record highs. As the Redmond, Washington-based software giant takes a dominant position in the cloud, investors have renewed their interest in Microsoft stock.Source: Shutterstock The recent run-up has put the near-term buy case for MSFT in doubt. However, due to its solid balance sheet and renewed growth, the case for holding MSFT stock has become more robust than ever. Microsoft Stock Is BackOnce written off as a company trapped in a declining PC business, Microsoft has successfully redefined itself. MSFT has now reached a market cap of $900 billion. This takes it to a record high for the equity. It has also regained the title of world's largest market cap.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 5 Cloud Stocks to Help Your Portfolio Fly To be sure, this is not the Microsoft that pushed me into Apple's (NASDAQ:AAPL) Mac ecosystem. No longer reliant on a PC monopoly of declining importance, it has turned itself into a leader in an increasingly influential cloud sector. Together with Amazon (NASDAQ:AMZN), it has become increasingly dominant in the enterprise information technology sector.The cloud in itself does not constitute a significant moat. Despite this, more than 800 CIOs cited Microsoft and Amazon as preferred vendors in over half of the top 30 IT products. Both companies have attracted this business--and built a moat--by continuously expanding their services.Thanks to a cash hoard that stood at $127.66 billion as of the end of 2018, MSFT can easily afford such expenditures. Last year, the company made $9.2 billion in corporate IT investments. Why MSFT Is a HoldAs a result, Microsoft has set records, rising for an eighth consecutive day. Despite its run, I do not think MSFT stock has become overvalued. The recent move higher takes its forward price-to-earnings (PE) ratio to just under 24 as of the time of this writing.Investors should also note that the company has placed itself on track to maintain double-digit profit growth. Analysts forecast profit increases of 14.2% for this year and 12.6% for fiscal 2020.Moreover, its cash position helps to give MSFT one of the strongest balance sheets in corporate America. That balance sheet has helped the company attain a AAA credit rating, a feat matched only by Johnson & Johnson (NYSE:JNJ).The key question is not whether one should buy Microsoft, but at what level. I agree with my InvestorPlace colleague Bret Kenwell who calls MSFT "a must-buy stock on a pullback." At these levels, I find it hard to conclude that Microsoft is anything but fairly valued. The forward PE ratio of almost 24 closely matches overall averages for the S&P 500.Still, I would buy if the stock stagnates for a few months or if it declines by at least 10%. I would also encourage long-term investors to stay put. In addition to the solid balance sheet, holders of Microsoft stock have benefitted from 15 straight years of dividend growth.This places it ten years away from dividend aristocrat status. It almost assures investors long-term holders that yields will rise from the more modest 1.6% levels of today. Though the buy case may appear tenuous for now, the hold case appears more solid than ever. The Bottom Line on Microsoft StockThe recent move higher in Microsoft has weakened the buy case for the equity, but its cloud dominance and strong balance sheet make MSFT a solid hold.Once written off as a laggard in a declining industry, a move into the cloud has again brought investors back to Microsoft stock. The stock continues to rise, and it has regained the title of world's largest market cap.However, its 14.2% growth rate combined with its forward PE of almost 24 places MSFT at fair value. A massive cash hoard, growing dividend, and solid balance sheet reinforce the case to stay in the stock. However, now is not the time to add to positions.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post Microsoft Stock Is Just Too Good to Buy Right Now appeared first on InvestorPlace.

  • Associated Pressyesterday

    FedEx, Johnson and Johnson slump while General Mills rises

    Stocks that moved substantially or traded heavily on Wednesday: FedEx Corp., down $6.34 to $175.07 The package delivery company said weaker global trade cut into profit and revenue, which fell shy of Wall ...

  • Bayer Stock Tumbles After Jury Finds Weed-Killer Roundup Caused Cancer
    Investor's Business Dailyyesterday

    Bayer Stock Tumbles After Jury Finds Weed-Killer Roundup Caused Cancer

    The market cap for Germany's Bayer shrank by more than $6 billion Wednesday after a jury said its Roundup weed killer caused cancer. Now, jurors must determine liability and damages.

  • Reutersyesterday

    US STOCKS-FedEx outlook weighs on Wall St ahead of Fed policy decision

    U.S. stocks fell on Wednesday after economic bellwether FedEx Corp's downbeat profit outlook raised concerns about global growth, while investors waited for more clarity on the Federal Reserve's interest rate forecasts for the rest of the year. The policy statement will also shed light on long-awaited details regarding the Fed's plans to stop reducing its holdings of Treasury bonds. "With the Fed, investors will be focusing on the growth outlook for 2019.

  • AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA
    Zacksyesterday

    AbbVie's Venclexta Multiple Myeloma Studies Put on Hold by FDA

    FDA places a partial clinical hold on all studies evaluating AbbVie's (ABBV) Venclexta (venetoclax) for the treatment of multiple myeloma.

  • Reutersyesterday

    US STOCKS-Wall St drops after weak FedEx outlook; Fed on tap

    U.S. stocks fell on Wednesday after economic bellwether FedEx issued a downbeat profit outlook and as investors waited for more clarity on the Federal Reserve's interest rate forecasts for the rest of the year. The policy statement will also shed light on long-awaited details regarding the Fed's plans to stop reducing its holdings of Treasury bonds. Hopes of a dovish stance from the Fed hit the rate-sensitive financial stocks, which fell 0.35 percent, while the bank subsector slipped 0.28 percent.

  • Stocks making the biggest moves premarket: General Mills, Johnson & Johnson, Viacom, Sony & more
    CNBC2 days ago

    Stocks making the biggest moves premarket: General Mills, Johnson & Johnson, Viacom, Sony & more

    These are the stocks posting the largest moves before the bell.

  • 3 Dividend Stocks Ideal for Retirees
    Motley Fool2 days ago

    3 Dividend Stocks Ideal for Retirees

    These two popular dividend stocks, and one you've probably never heard of, should fit a retiree's portfolio.

  • Analysts Are Divided on Johnson & Johnson Stock
    Market Realist2 days ago

    Analysts Are Divided on Johnson & Johnson Stock

    How Major Pharmaceutical Stocks Are Positioned This Month(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts have given Johnson & Johnson (JNJ) a 12-month consensus target price of $144.71, 5.50% higher

  • Johnson & Johnson to Host Investor Conference Call on First-Quarter Results
    PR Newswire2 days ago

    Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

    The webcast and presentation material are accessible at Johnson & Johnson's website www.investor.jnj.com. A replay of the webcast will be available approximately three hours after the conference call concludes.

  • Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know
    Zacks3 days ago

    Johnson & Johnson (JNJ) Stock Sinks As Market Gains: What You Should Know

    Johnson & Johnson (JNJ) closed the most recent trading day at $137.35, moving -0.19% from the previous trading session.

  • 3 Consumer Staples Stocks to Trade in 2019
    InvestorPlace3 days ago

    3 Consumer Staples Stocks to Trade in 2019

    So far in 2019, the bulls have been in complete control over the stock market. This strength comes despite there not yet being a resolution to the global tariff war and while we await the conclusion of Brexit. However, when things go south for stocks the breakdown comes fast and portfolios suffer severe consequences if investors didn't balance them properly -- that brings us to consumer staples stocks.Some sectors are better at withstanding selling pressure than others. During a selloff, momentum stocks like Amazon (NASDAQ:AMZN) and Chipotle (NYSE:CMG) likely fall much faster than older, dividend-paying stocks. When times are tough, consumer stocks hold their value much better than most others.So why isn't everyone only in consumer staples stocks? Because what makes them almost bullet proof on the way down also slows them down during rallies. Traders are now on an upswing, so consumer stocks are generally lagging.InvestorPlace - Stock Market News, Stock Advice & Trading TipsBut therein lies the opportunity.This year, the Consumer Staples Select Sector SPDR ETF (NYSEARCA:XLP) is up only half as much as the S&P 500. So if the bulls remain in control for the next two weeks, consumer staple stocks will have the opportunity of a catch-up rally.Furthermore, they're worth snatching up because there are tremendous risks that still loom over the global business sentiment. Yes, stocks are rising now but most of the risks that caused the selling last year are still here. Only the threat from a combative U.S. Fed has abated. So if the sellers come back online, then the consumer staple investments will hold up better than the general markets, so they are a safer bet. * 10 Dividend Stock Winners These three consumer stocks stand out in the sector: Mondelez International (NASDAQ:MDLZ), Johnson & Johnson (NYSE:JNJ) and the Consumer Staples ETF (NYSEARCA:XLP). Here's more about each. Mondelez (MDLZ)Source: Shutterstock Mondelez made news last year as it invested $4 billion into Canopy Growth (NASDAQ:CGC), which quickly became a go-to cannabis stock to own (it had the best balance sheet of them all). So clearly, MDLZ is a company that is not afraid to take risks. And if the hype of the potential revenues from pot-related products and services is actually true, then MDLZ will get a handsome return on its investment.Meanwhile, MDLZ stock has its own reasons for ownership. It is now trading above the zone around $45.50, which has been resistance for years. So now it has solid footing below to attack the all-time highs. About a month ago it almost broke out of them, so it could be reloading to set new highs soon. If the geopolitical headlines comply, MDLZ stock should blaze a new trail soon. As long as it's above $45 per share, this is a real possibility.MDLZ sells at a price-to-earnings ratio of 25, which is in-line with the sector. So even though its management acts like it's a momentum company, the stock is not as frothy as one. Johnson & Johnson (JNJ)Source: Shutterstock Johnson & Johnson has been a proven performer for over a century, so the effects of last year's headline over the talcum lawsuits will inevitably fade. This is not to minimize the issue and its effects on those who suffered, but JNJ stock will recover from it. Owning JNJ stock now offers the opportunity to ride the snapback rally. * 7 Dividend Stocks to Buy Today JNJ is not screaming cheap, but the macroeconomic correction from last year and JNJ-specific headlines have shaken the weak hands from the stock. This makes for a strong base going forward. And the sellers will be less likely to panic at the first sign of weakness. Consumer Staples Select Sector SPDR ETFEven though buying the XLP is similar to investing individually in MDLZ or JNJ, doing so diffuses the risks of individual headlines. There are heavyweight tickers in the XLP, but none that would bring down the whole exchange-traded fund. They do, however, trade in unison, so that risk remains.But from here, the XLP chart looks bullish. Even though it is lagging the SPY in its bounce off the December lows, the XLP is setting higher lows and has a breakout neckline just above current levels. If the bulls can breakout of $55 per share they can overshoot to target the all-time highs from November. There will be resistance along the way, especially around $56 per share … this is where the real selling began last year.So why expect a move now?The XLP chart has set higher lows and lower highs, thereby bringing it to a point. These usually are precursors to big moves because the energy needs to disperse quickly. So if the stock market, in general, continues this breakout, the XLP will eventually finish its own breakout upwards.Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him as @racernic on Twitter and Stocktwits. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 5 of the Best Stocks to Buy Under $10 * 7 Single-Digit P/E Stocks With Massive Upside * 7 Best Quantum Computing Stocks Trading Today Compare Brokers The post 3 Consumer Staples Stocks to Trade in 2019 appeared first on InvestorPlace.

  • Are Hedge Funds Right About Berkshire Hathaway Inc. (BRK-B)?
    Insider Monkey3 days ago

    Are Hedge Funds Right About Berkshire Hathaway Inc. (BRK-B)?

    Reputable billionaire investors such as Jim Simons, Cliff Asness and David Loeb generate exorbitant profits for their wealthy accredited investors (a minimum of $1 million in investable assets would be required to invest in a hedge fund and most successful hedge funds won't accept your savings unless you commit at least $5 million) by pinpointing winning […]

  • Investing.com3 days ago

    UnitedHealth Shares Finding Their Mojo Again

    Investing.com - UnitedHealth Group (NYSE:UNH) has been a big reason why the Dow has held its own lately.

  • The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
    Zacks4 days ago

    The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

    The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J

  • 5 Recession-Proof Stocks
    Motley Fool6 days ago

    5 Recession-Proof Stocks

    Almost no one is thinking about the fifth company, and therein lies opportunity.

  • TheStreet.com6 days ago

    The Rally in Johnson & Johnson Looks Like it has Run Its Course

    In Thursday night's Mad Money program, Jim Cramer told viewers that there are still plenty of opportunities for individuals to buy individual stocks. Cramer identified five risks that investors need to consider. In this Japanese candlestick chart of JNJ, below, we can see the price action of the last six months (only looking at six months of candles allows us to see the patterns better).